Eurobio Scientific SA
PAR:ALERS

Watchlist Manager
Eurobio Scientific SA Logo
Eurobio Scientific SA
PAR:ALERS
Watchlist
Price: 25.65 EUR 7.55%
Market Cap: 256.6m EUR

EV/EBIT
Enterprise Value to EBIT

17.7
Current
9.9
Median
3.8
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
17.7
=
Enterprise Value
249.3m EUR
/
EBIT
14.1m EUR
Market Cap EV/EBIT
FR
Eurobio Scientific SA
PAR:ALERS
257.2m EUR 17.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -209 659.2
US
Abbvie Inc
NYSE:ABBV
357.9B USD 25
US
Amgen Inc
NASDAQ:AMGN
164.2B USD 28.8
US
Gilead Sciences Inc
NASDAQ:GILD
138.5B USD 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.1B USD 27.7
US
Epizyme Inc
F:EPE
94.1B EUR -518.5
AU
CSL Ltd
ASX:CSL
121.8B AUD 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
69.7B USD 11.4
US
Seagen Inc
F:SGT
39.3B EUR -55
NL
argenx SE
XBRU:ARGX
33B EUR -2 323.6
EBIT Growth EV/EBIT to Growth
FR
Eurobio Scientific SA
PAR:ALERS
Average EV/EBIT: 20.9
17.7
34%
0.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 659.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
25
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.7
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.4
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 323.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
10.4
2-Years Forward
EV/EBIT
8.7
3-Years Forward
EV/EBIT
7.2